Kates R E, Keefe D L, Winkle R A
Clin Pharmacol Ther. 1983 Jan;33(1):28-34. doi: 10.1038/clpt.1983.4.
Lorcainide disposition kinetics were studied after intravenous and oral administration to patients with ventricular arrhythmias. After intravenous doses ranging from 100 to 200 mg, blood samples were drawn and plasma was analyzed for lorcainide concentration by high-pressure liquid chromatography. A three-compartment model was used to fit the data. The model-independent calculated values for clearance, steady-state volume of distribution, and terminal half-life were 14.4 +/- 3.28 ml/min/kg, 6.33 +/- 2.23 l/kg, and 7.8 +/- 2.2 hr. After nine doses of oral lorcainide (100 mg every 12 hr) blood samples were drawn and analyzed for lorcainide and its active metabolite, norlorcainide. The lorcainide and norlorcainide half-lifes were 9.6 +/- 2.8 and 26.8 +/- 8.2 hr. Mean steady-state level of norlorcainide was 2.2 +/- 0.9 times the level of lorcainide. The data suggest that the clearance of lorcainide decreases with time during long-term dosing.
对室性心律失常患者静脉注射和口服洛卡尼后,研究了其处置动力学。静脉注射剂量为100至200毫克后,采集血样,并用高压液相色谱法分析血浆中洛卡尼的浓度。采用三室模型拟合数据。清除率、稳态分布容积和终末半衰期的模型独立计算值分别为14.4±3.28毫升/分钟/千克、6.33±2.23升/千克和7.8±2.2小时。口服九剂洛卡尼(每12小时100毫克)后,采集血样并分析洛卡尼及其活性代谢产物去甲洛卡尼。洛卡尼和去甲洛卡尼的半衰期分别为9.6±2.8小时和26.8±8.2小时。去甲洛卡尼的平均稳态水平是洛卡尼水平的2.2±0.9倍。数据表明,长期给药期间洛卡尼的清除率随时间降低。